[Anesthesia for electroconvulsive therapy]

[Practice of anaesthesia for electroconvulsive therapy]

Electroconvulsive therapy (ECT) is an established therapeutic method for the treatment of severe mental disorders refractory to pharmaco- and psychotherapy. ECT is a first-line treatment option in delusional disorders, severe depression with acute suicidal tendency or life-threatening catatonia. Usually, ECT is performed as a treatment series. Under short-term anaesthesia and muscle relaxation, tonic-clonic seizures are induced using an external stimulation electrode. Convulsion can be exerted by uni- or bipolar stimulation using an electric charge up to 1000 millicoulomb (mC) with an amperage of 900 mA. Muscular relaxation is necessary to prevent injuries caused by uncontrolled movements during convulsion. During paralysis, consciousness is blocked by general anaesthesia, although ECT is associated with antegrade amnesia for seizure induction and the seizure itself. In the context of ECT, the ideal hypnotic should be characterised by rapid onset, short duration of action and negligible anticonvulsive effects (i.e., least possible impact on seizure quality and duration). As mutual awareness of psychiatric and anaesthesiologic techniques is essential for safe and effective conduction of ECT, this article presents ECT both from the psychiatrist's and the anaesthesiologist's perspective.

[Electroconvulsive therapy in pregnancy: case report and interdisciplinary treatment suggestions]

Hintergrund

Psychische Störungen in der Schwangerschaft sind häufig. Besonders bei schweren affektiven oder psychotischen Störungen mit Notwendigkeit eines raschen Ansprechens kann eine Elektrokonvulsionstherapie (EKT) indiziert sein. Dazu vorliegende Übersichtsartikel unterscheiden sich methodisch stark, was zu unterschiedlichen Schlussfolgerungen hinsichtlich der Anwendung der EKT bei Schwangerschaft führt.

Ziel der Arbeit

Darstellung eines neuen klinischen Falls sowie interdisziplinärer Behandlungsvorschläge zur sicheren Anwendung der EKT bei Schwangerschaft.

Methoden

Fallbericht und selektive Literaturübersicht unter besonderer Berücksichtigung der existierenden systematischen Reviews.

Ergebnisse und Diskussion

Die aktuelle Kasuistik zeigt die potenziell hohe Wirksamkeit sowie die für Mutter und Fetus sichere Anwendung der EKT während der Schwangerschaft. Die in der Literatur beschriebenen unerwünschten Ereignisse entsprechen qualitativ weitgehend den Risiken bei schwerer psychischer Störung in der Schwangerschaft. Zur besseren Nutzen-Risiko-Abwägung wären größere Fall-Kontroll-Studien wünschenswert. Bei sorgfältiger Indikationsstellung, guter interdisziplinärer Abstimmung und Beachtung der Besonderheiten in der praktischen Durchführung ist die EKT auch in der Schwangerschaft eine sinnvolle Behandlungsoption.

[Treatment against the patient's will exemplified by electroconvulsive therapy : Clinical, legal and ethical aspects]

BACKGROUND

Severe affective and psychotic disorders may be accompanied by legal incapacity. If in this case the patient refuses treatment and in parallel there is a risk of serious damage to health, treatment can be carried out against the patient's non-autonomous will under defined prerequisites. Due to its good and partly superior effectiveness in the treatment of severe and pharmacotherapy-resistant affective and psychotic disorders, electroconvulsive therapy (ECT) is an important treatment option in such constellations.

AIM

Description of the general principles and prerequisites of therapeutic measures against the patient's will.

METHODS

Based on a case report, the application of ECT as a medical measure against the patient's will is discussed and assessed in an interdisciplinary approach from clinical, legal, and ethical perspectives.

RESULTS AND DISCUSSION

The (empirical) evidence on the general effectiveness of ECT, as well as its application against the will of patients with legal incapacity, clearly shows a positive benefit-risk ratio. When performed against the patient's will, ECT as all compulsory medical interventions, represents a severe encroachment on the individual's fundamental rights of both physical integrity and self-determination. Nevertheless, its application may be medically indicated, legally admissible and ethically appropriate in individual cases to prevent the threat of serious damage to the patient's health. Ethical and legal prerequisites of treatment against the patient's will should be evaluated by a multiprofessional team and the patient's legal guardian should be involved from an early stage.

[Transcranial alternating current stimulation. Entrainment and function control of neuronal networks]

Transcranial alternating current stimulation (tACS) is a new technique for the modulation of oscillatory brain activity as measured in the electroencephalogram (EEG). In contrast to well-established stimulation techniques, such as transcranial direct current stimulation and transcranial magnetic stimulation, tACS applies a sinusoidal alternating current at a specific frequency. This enables the modulation of the amplitude and frequency of endogenous brain oscillations as well as related cognitive processes. Therefore, the use of tACS has the possibility to evaluate well-known correlations between brain oscillations and cognitive processes in terms of causality. Such causal relationships have been documented in numerous neurocognitive studies on sensory, motor and perceptual processes; however, the clinical application of tACS is still in its infancy. In principle, any pathology that can reliably be connected with brain oscillations of a defined frequency is treatable. A current main focus of clinical research is on symptoms of Parkinson's disease and to a lesser degree, tinnitus. For an effective application of tACS it is important to choose the electrode positions as well as the frequency, intensity and duration of the stimulation in a theory-based and symptom-related manner. A successful therapeutic intervention requires the persistence of the tACS effect after stimulation has ceased. A mechanism that offers not only an explanation to the origin of persistent tACS effects but is also of high therapeutic benefit is neural plasticity. Therefore, one current focus of research aims at a better understanding of tACS after effects.

Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients

BACKGROUND

Propofol is often used as an anesthetic agent for electroconvulsive therapy (ECT). In recent studies, propofol was shown to possess significant seizure-shortening properties during ECT. "Valproate" is a mood stabilizer used mainly in the treatment of bipolar affective disorder. It is reported that valproate, being an anticonvulsant, raises the seizure threshold, thus decreases the efficacy of ECT treatment.

AIM

The purpose of our study was to compare the dose of propofol in valproate-using patients and valproate-free patients.

METHODS

In an open design, 17 patients with bipolar affective disorder manic episodes who were to be treated with valproate and ECT in combination, were compared with 16 manic-episode patients who were to be treated with ECT but not valproate. The two groups were compared on the basis of electroencephalography-registered seizure duration and the propofol dosage required to induce anesthesia.

RESULTS

Valproate, compared with no valproate treatment, results in a decrease in the propofol dose required to induce anesthesia. In the valproate group of study participants, seizure duration was significantly shorter than in the valproate-free group.

CONCLUSION

The results suggest that valproate reduces the dose of propofol required for anesthesia during ECT treatment in patients with bipolar affective disorder manic episodes. Although propofol is a safe and efficacious anesthetic for ECT treatment, lower doses of propofol should be used to induce anesthesia for patients under valproate treatment. When the clinician needs to prolong seizure duration in patients treated with valproate, interruption of the valproate treatment or an anesthetic agent other than propofol should be considered.